Invokana Lawsuit Help – Diabetes Medications, Including Invokana, May Result in Ketoacidosis
The Law Firm of Eric H. Weinberg is currently evaluating lawsuits on behalf of those injured after taking type 2 diabetes medications known as SGLT2 inhibitors including:
- Invokana (canagliflozin)
- Invokamet (canagliflozin/metformin combination)
- Farxiga (dapagliflozin)
- Xigduo XR (dapagliflozin/metformin combination)
- Jardiance (empagliflozin)
- Glyxambi (empagliflozin/linagliptin combination)
If you or a loved one has suffered ketoacidosis after taking Invokana, or another SGLT2 inhibitor, and you have a question regarding your legal rights, please contact us toll free at 1- 877-934-627 for a free lawsuit case evaluation.
FDA Safety Communication Regarding Invokana and Other SGLT2 Inhibitors
In a Drug Safety Communication dated May 15, 2015, the U.S. Food and Drug Administration (FDA) warned that the type 2 diabetes medications canagliflozin (marketed as Invokana), dapagliflozin (marketed as Farxiga), and empagliflozin (marketed as Jardiance) may lead to a serious medical condition known as ketoacidosis. Ketoacidosis is a condition that occurs when the body produces high levels of blood acids called ketones, and may require hospitalization.
The FDA cautions that patients should be alert for the signs of ketoacidosis and seek medical attention if they experience symptoms such as difficulty breathing, nausea, vomiting abdominal pain, confusion, and unusual fatigue or sleepiness. Patients are also cautioned that they should not stop or change their diabetes medicines without first talking to their doctor.
What are SGLT2 Inhibitors?
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a class of drugs approved for use with diet and exercise to lower blood sugar levels in adults diagnosed with type 2 diabetes. SGLT2 inhibitors lower blood sugar by causing the kidneys to remove sugar from the body through the urine. The drugs are marketed to patients as single-ingredient medications, and also in combination with other diabetes medicines such as metformin and linagliptin. SGLT2 inhibitors have not been approved by the FDA for use in type 1 diabetes patients.
The FDA Continues to Investigate SGLT2 Inhibitor and Ketoacidosis Link
Between March 2013 and June 6, 2014, twenty cases of diabetic ketoacidosis (DKA), ketoacidosis, or ketosis in connection with SGLT2 inhibitors including Invokana, were reported to the FDA’s Adverse Event Reporting System (FAERS). In all twenty cases, patient hospitalization was required to treat the condition. The FDA reports that it has received more reports of DKA, and continues to investigate this serious safety issue.
Contact The Weinberg Law Firm for a Free Invokana Lawsuit or SGLT2 Inhibitor Lawsuit Consult.
Attorney Eric Weinberg has represented thousands of patients injured by drug adverse events including for example, the products Vioxx, Baycol, Pradaxa, Ortho Evra, and blood clotting products. If you or a loved one developed ketoacidosis after taking Invokana, Invokamet, or another SGLT2 inhibitor, please contact our firm for a free drug lawsuit evaluation by calling us toll free at 1-877-934-6274. You can also contact a Weinberg Firm lawyer by submitting our easy-to-use free legal case evaluation form.
